Nov 08, 2023 5:30pm EST Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Oct 17, 2023 9:15am EDT Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Sep 21, 2023 5:00pm EDT Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Sep 05, 2023 6:41pm EDT Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units
Sep 05, 2023 7:30am EDT Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
Aug 17, 2023 5:30pm EDT Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
